| Year |
Citation |
Score |
| 2021 |
Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, et al. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation. PMID 33767401 DOI: 10.1038/s41409-021-01255-4 |
0.316 |
|
| 2020 |
Salas MQ, Atenafu EG, Bascom O, Wilson L, Lam W, Law AD, Pasic I, Kim DDH, Michelis FV, Al-Shaibani Z, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Alibhai SMH, et al. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 32606454 DOI: 10.1038/S41409-020-0979-1 |
0.309 |
|
| 2020 |
Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, Gerbitz A, Al-Shaibani Z, Viswabandya A, Dong Hwan Kim D, Lam W, Law A, Mattsson J, Kumar R, Lipton JH. Clinical prevalence and outcome of cardiovascular events in the first 100 days post allogeneic HSCT. European Journal of Haematology. PMID 32599663 DOI: 10.1111/Ejh.13482 |
0.302 |
|
| 2020 |
Salas MQ, Wilson Lam SC, Pasic I, Gerbitz A, Michelis FV, Kim DDH, Al-Shaibani Z, Howard Lipton J, Mattsson J, Kumar R, Viswabandya A, Datt A. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32422253 DOI: 10.1016/J.Bbmt.2020.04.021 |
0.373 |
|
| 2020 |
Pasic I, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, Michelis FV. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology. PMID 32382774 DOI: 10.1007/S00277-020-04033-2 |
0.364 |
|
| 2019 |
Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, Kim DD, Thyagu S, Messner HA, Michelis FV. Influence of FLT3-ITD and NPM1 Status on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Cytogenetically Normal AML. European Journal of Haematology. PMID 30706524 DOI: 10.1111/Ejh.13216 |
0.352 |
|
| 2017 |
Pasic I, Lipton JH. Current approach to the treatment of chronic myeloid leukaemia. Leukemia Research. 55: 65-78. PMID 28135648 DOI: 10.1016/J.Leukres.2017.01.005 |
0.309 |
|
| 2014 |
Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, Ishkanian A, Sendorek DH, Pasic I, Lam WL, Jurisica I, van der Kwast T, Milosevic M, Boutros PC, Bristow RG. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget. 5: 11081-90. PMID 25415046 DOI: 10.18632/Oncotarget.2404 |
0.362 |
|
| 2012 |
Porat RM, Pasic I, Shlien A, Gokgoz N, Andrulis I, Wunder JS, Malkin D. Abstract 1447: Investigating susceptibility to sporadic osteosarcoma by genome-wide copy number analysis Cancer Research. 72: 1447-1447. DOI: 10.1158/1538-7445.Am2012-1447 |
0.561 |
|
| 2011 |
Porat RM, Pasic I, Shlien A, Golgoz N, Andrulis I, Wunder JS, Malkin D. Abstract 5334: Genome-wide copy number analysis reveals two novel loci for susceptibility to sporadic osteosarcoma Cancer Research. 71: 5334-5334. DOI: 10.1158/1538-7445.Am2011-5334 |
0.561 |
|
| 2010 |
Durbin AD, Pasic I, Wong DK, Hannigan GE, Malkin D. The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. Cell Cycle (Georgetown, Tex.). 9: 1951-9. PMID 20495362 DOI: 10.4161/Cc.9.10.11554 |
0.472 |
|
| 2010 |
Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A, Malkin D. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Research. 70: 160-71. PMID 20048075 DOI: 10.1158/0008-5472.Can-09-1902 |
0.534 |
|
| 2008 |
Pasic I, Shlien A, Novokmet A, Zhang C, Tabori U, Pinto D, Scherer SW, Malkin D. CONTRIBUTION OF DNA COPY-NUMBER VARIATION (CNV) TO CANCER SUSCEPTIBILITY AND LARGE-SCALE GENOME ALTERATIONS IN OSTEOSARCOMA (OS) Clinical & Investigative Medicine. 31: 19. DOI: 10.25011/CIM.V31I4.4821 |
0.34 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2020 |
Nampoothiri RV, Chen C, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis F, Kim DDH, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Kumar R, Thyagu S. Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre Blood. 136: 23-24. DOI: 10.1182/BLOOD-2020-142982 |
0.295 |
|
| 2021 |
Pasic I, Paulson K, Dozois G, Schultz KR, Lipton JH, Kumar R. Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. Leukemia & Lymphoma. 1-9. PMID 33827366 DOI: 10.1080/10428194.2021.1910688 |
0.294 |
|
| 2017 |
Pasic I, Man Wong K, John Lee J, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, Guo G, et al. Two BRM Promoter Polymorphisms Predict Poor Survival in Patients with Hepatocellular Carcinoma. Molecular Carcinogenesis. PMID 28892201 DOI: 10.1002/Mc.22736 |
0.282 |
|
| 2020 |
Madsen K, Cote G, Pelletier K, Kitchlu A, Chen S, Mattsson J, Pasic I. Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant Blood. 136: 16-17. DOI: 10.1182/blood-2020-136746 |
0.279 |
|
| 2023 |
Kim KH, Kim T, Novitzky-Basso I, Lee H, Yoo Y, Ahn JS, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, et al. Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup. Haematologica. PMID 36727396 DOI: 10.3324/haematol.2022.281806 |
0.276 |
|
| 2022 |
Kim DDH, Novitzky Basso I, Kim TS, Yi SY, Kim KH, Murphy T, Chan S, Minden M, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, et al. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. Ejhaem. 3: 873-884. PMID 36051057 DOI: 10.1002/jha2.466 |
0.273 |
|
| 2021 |
Salas MQ, Atenafu EG, Law AD, Lam W, Pasic I, Chen C, Dong Hwan Kim D, Michelis FV, Gerbitz A, Lipton JH, Mattsson J, Kumar R, Viswabandya A. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy. 27: 428.e1-428.e9. PMID 33965185 DOI: 10.1016/j.jtct.2021.02.007 |
0.272 |
|
| 2022 |
Madsen K, Pelletier K, Côté G, Kitchlu A, Chen S, Mattsson J, Pasic I. Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. Bone Marrow Transplantation. PMID 35752740 DOI: 10.1038/s41409-022-01744-0 |
0.272 |
|
| 2001 |
Hill SR, Leung SS, Quercia NL, Vasiliauskas D, Yu J, Pasic I, Leung D, Tran A, Romans P. Ikirara insertions reveal five new Anopheles gambiae transposable elements in islands of repetitious sequence. Journal of Molecular Evolution. 52: 215-31. PMID 11428459 DOI: 10.1007/S002390010150 |
0.271 |
|
| 2020 |
Nampoothiri RV, Chen S, Pasic I, Al-Shaibani Z, Lam W, Michelis FV, Kim DDH, Viswabandya A, Gerbitz A, Lipton JH, Kumar R, Mattsson J, Law AD. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematology/Oncology and Stem Cell Therapy. PMID 33049225 DOI: 10.1016/j.hemonc.2020.09.001 |
0.271 |
|
| 2021 |
Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, Kumar R, Michelis FV, Mattsson J. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. European Journal of Haematology. PMID 34905239 DOI: 10.1111/ejh.13735 |
0.267 |
|
| 2020 |
Novitzky-Basso IN, Mats R, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DDH, Kumar R, Michelis F, Mattsson J. ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors Blood. 136: 31-31. DOI: 10.1182/blood-2020-139736 |
0.265 |
|
| 2023 |
Carreira AS, Salas MQ, Remberger M, Novitzky-Basso I, Law AD, Lam W, Pasic I, Mazzulli T, Cserti-Gazdewich C, Kim DDH, Michelis FV, Viswabandya A, Gerbitz A, Lipton JH, Kumar R, et al. Interaction between High-Dose Intravenous Busulfan and Post-Transplant Cyclophosphamide on Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. PMID 37437765 DOI: 10.1016/j.jtct.2023.07.007 |
0.261 |
|
| 2021 |
Novitzky-Basso I, Remberger M, Chen C, Pasić I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, Kumar R, Mattsson J, Michelis FV. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. European Journal of Haematology. PMID 34606661 DOI: 10.1111/ejh.13714 |
0.257 |
|
| 2020 |
Alhumaid M, Daher-Reyes GS, Law A, Viswabandya A, Gerbitz A, Michelis F, Novitzky-Basso IN, Lipton JH, Mattson J, Pasic I, Kumar R, Lam W, Al-Shaibani Z, Sibai H, Kim DDH. Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission Blood. 136: 36-37. DOI: 10.1182/BLOOD-2020-136122 |
0.257 |
|
| 2023 |
Seftel MD, Pasic I, Parmar G, Bucher O, Allan DS, Bhella S, Hay KA, Ikuomola O, Musto G, Prica A, Richardson E, Truong TH, Paulson K. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study. Current Oncology (Toronto, Ont.). 30: 9953-9967. PMID 37999143 DOI: 10.3390/curroncol30110723 |
0.255 |
|
| 2023 |
Pereira MP, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplantation and Cellular Therapy. PMID 37579919 DOI: 10.1016/j.jtct.2023.08.009 |
0.254 |
|
| 2024 |
Queralt Salas M, Alfaro-Moya T, Atenafu EG, Datt Law A, Lam W, Pasic I, Novitzky-Basso I, Santos Carreira A, Chen C, Michelis FV, Gerbitz A, Howard Lipton J, Kim DDH, Kumar R, Mattsson J, et al. Outcomes of ATG-PTCY-CSA vs. ATG-based Prophylaxis for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: ATG-PTCY-CsA for PB MUD allo-HCT. Transplantation and Cellular Therapy. PMID 38281592 DOI: 10.1016/j.jtct.2024.01.075 |
0.251 |
|
| 2022 |
Salas MQ, Pasic I, Remberger M, Novitzky-Basso I, Law AD, Lam W, Chen C, Kim DDH, Michelis FV, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J. Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy. PMID 35139398 DOI: 10.1016/j.jtct.2022.02.001 |
0.248 |
|
| 2020 |
Novitzky-Basso IN, Pasic I, Al-Shaibani Z, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Michelis F, Kim DDH. Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment Blood. 136: 1-2. DOI: 10.1182/BLOOD-2020-138927 |
0.248 |
|
| 2022 |
Pelletier K, Côté G, Madsen K, Chen S, Kim SJ, Chan CT, Mattsson J, Pasic I, Kitchlu A. Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. Clinical Kidney Journal. 15: 1583-1592. PMID 35892015 DOI: 10.1093/ckj/sfac091 |
0.248 |
|
| 2021 |
Carreira AS, Salas MQ, Remberger M, Basso IN, Law AD, Lam W, Pasic I, Kim D, Michelis FV, Viswabandya A, Gerbitz A, Lipton JH, Husain S, Kumar R, Mattsson J. Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: a Single-Center Study. Transplantation and Cellular Therapy. PMID 34656808 DOI: 10.1016/j.jtct.2021.10.008 |
0.246 |
|
| 2023 |
Salas MQ, Atenafu EG, Pasic I, Bascom O, Wilson L, Lam W, Law AD, Chen C, Novitzky-Basso I, Kim DDH, Gerbitz A, Viswabandya A, Michelis FV, Lipton JH, Mattsson J, et al. HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 37620424 DOI: 10.1038/s41409-023-02088-z |
0.245 |
|
| 2021 |
Novitzky-Basso I, Chen C, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Pre-transplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. European Journal of Haematology. PMID 34076909 DOI: 10.1111/ejh.13673 |
0.241 |
|
| 2024 |
Sayyed A, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I. Pre-transplant blinatumomab improves outcomes in B-cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation. Transplantation and Cellular Therapy. PMID 38462215 DOI: 10.1016/j.jtct.2024.03.004 |
0.237 |
|
| 2021 |
Al-Shaibani E, Bautista R, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients. Clinical Lymphoma, Myeloma & Leukemia. PMID 34866020 DOI: 10.1016/j.clml.2021.11.004 |
0.235 |
|
| 2021 |
Mar Linn S, Vasudevan Nampoothiri R, Chen C, Pasic I, Al-Shaibani Z, Lam W, Datt Law A, Michelis FV, Kim DDH, Gerbitz A, Lipton J, Kumar R, Mattsson J, Viswabandya A. Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematology/Oncology and Stem Cell Therapy. PMID 34856195 DOI: 10.1016/j.hemonc.2021.09.008 |
0.233 |
|
| 2022 |
Vasudevan Nampoothiri R, Pasic I, Law AD, Lam W, Chen C, Michelis FV, Kim DDH, Gerbitz A, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy-Related Hematologic Malignancies Developing After Multiple Myeloma. European Journal of Haematology. PMID 35100661 DOI: 10.1111/ejh.13750 |
0.233 |
|
| 2023 |
Pang I, Chen P, Trinh GV, Remberger M, Novitzky-Basso I, Gerbitz A, Kim DD, Kumar R, Lam W, Law AD, Lipton JH, Viswabandya A, Pasic I, Mattsson J, Michelis FV. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data. European Journal of Haematology. PMID 37830403 DOI: 10.1111/ejh.14117 |
0.231 |
|
| 2021 |
Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W, Law AD, Michelis FV, Thyagu S, Kim DDH, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Kumar R. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 34108675 DOI: 10.1038/s41409-021-01362-2 |
0.222 |
|
| 2021 |
Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, Kim DDH, Lipton JH, Michelis FV. Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. Hematology/Oncology and Stem Cell Therapy. PMID 33684377 DOI: 10.1016/j.hemonc.2021.01.001 |
0.218 |
|
| 2021 |
Al-Shaibani E, Cyriac S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 33678592 DOI: 10.1016/j.clml.2021.01.022 |
0.217 |
|
| 2024 |
Vasudevan Nampoothiri R, Avery L, Pasic I, Prassas I, Diamandis E, Michelis FV. Multiplex proteomics in the identification of potential biomarkers of very severe sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in allogeneic hematopoietic cell transplant patients treated with defibrotide. Acta Haematologica. PMID 38330921 DOI: 10.1159/000535706 |
0.215 |
|
| 2023 |
Pasic I, Ren AH, Nampoothiri RV, Prassas I, Lipton JH, Mattsson J, Diamandis EP, Michelis FV. Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. Clinical Chemistry and Laboratory Medicine. PMID 36655501 DOI: 10.1515/cclm-2022-0916 |
0.212 |
|
| 2023 |
Madsen K, Lee K, Chen S, Chen C, Law AD, Gerbitz A, Kumar R, Kim D, Lam W, Pasic I, Viswabandya A, Michelis FV, Nampoothiri RV, Lipton JH, Novitzky-Basso I, et al. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 31: 564. PMID 37676349 DOI: 10.1007/s00520-023-08022-9 |
0.211 |
|
| 2023 |
Novitzky-Basso I, Lam W, Chiarello C, Pasic I, Law AD, Michelis FV, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Messner HA, Marras TK, Mittoo S, Kim DDH. Prognostic implication of pre-transplant FEV on long-term outcomes following allogeneic hematopoietic stem cell transplantation. European Journal of Haematology. PMID 37491877 DOI: 10.1111/ejh.14062 |
0.209 |
|
| 2023 |
Novitzky-Basso I, Patriquin C, Linn SM, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD. Transplantation and Cellular Therapy. PMID 37797719 DOI: 10.1016/j.jtct.2023.09.021 |
0.204 |
|
| 2023 |
Linn SM, Novitzky-Basso I, Abduljalil O, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Kim DDH. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematology/Oncology and Stem Cell Therapy. 17: 60-71. PMID 37581458 DOI: 10.56875/2589-0646.1111 |
0.201 |
|
| 2023 |
Alfaro Moya T, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, Pasic I, Novitzky-Basso I, Michelis FV. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. European Journal of Haematology. PMID 37461810 DOI: 10.1111/ejh.14041 |
0.194 |
|
| 2020 |
Nampoothiri RV, Ho L, McEwan C, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Kim DDH, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Kumar R. Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study Blood. 136: 18-18. DOI: 10.1182/BLOOD-2020-142302 |
0.184 |
|
| 2020 |
Linn SM, Abduljalil O, Novitzky-Basso IN, Nampoothiri RV, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattson J, Kim DDH. Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib Blood. 136: 17-18. DOI: 10.1182/BLOOD-2020-142182 |
0.184 |
|
| 2021 |
Lee K, Madsen K, Chen S, Law AD, Gerbitz A, Kumar R, Kim DD, Lam W, Michelis FV, Pasic I, Viswabandya A, Lipton JH, Mattson J. Weight Loss after Allogeneic Stem Cell Transplantation Is Associated with Increased Mortality Transplantation and Cellular Therapy. 27: S181-S182. DOI: 10.1016/S2666-6367(21)00224-4 |
0.18 |
|
| 2002 |
Stavropoulos DJ, Bradshaw PS, Li X, Pasic I, Truong K, Ikura M, Ungrin M, Meyn MS. The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Human Molecular Genetics. 11: 3135-44. PMID 12444098 DOI: 10.1093/Hmg/11.25.3135 |
0.179 |
|
| 2021 |
Law AD, Bhella S, Pasic I, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Kumar R, Lipton JH, Mattsson J, Kim DDH. Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology. PMID 33710366 DOI: 10.1007/s00277-021-04480-5 |
0.178 |
|
| 2023 |
Al-Shaibani E, Chen S, Chen C, Pasic I, Michelis FV, Lam W, Law A, Novitzky-Basso I, Gerbitz A, Kim DD, Viswabandya A, Lipton JH, Mattson J, Kumar R. Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. Annals of Hematology. PMID 36820907 DOI: 10.1007/s00277-023-05135-3 |
0.173 |
|
| 2022 |
Salas MQ, Atenafu EG, Pasic I, Al-Shaibani E, Bascom O, Wilson L, Chen C, Law AD, Lam W, Novitzky-Basso I, Kim DDH, Gerbitz A, Viswabandya A, Michelis FV, Lipton JH, et al. Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults. Bone Marrow Transplantation. PMID 36526806 DOI: 10.1038/s41409-022-01892-3 |
0.162 |
|
| 2023 |
Linn SM, Novitzky-Basso I, Patriquin C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure. Leukemia Research. 134: 107387. PMID 37734221 DOI: 10.1016/j.leukres.2023.107387 |
0.151 |
|
| 2023 |
Mittal A, Solera JT, Ferreira VH, Kothari S, Kimura M, Pasic I, Mattsson JI, Humar A, Kulasingam V, Ierullo M, Kumar D, Hosseini-Moghaddam SM. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy. PMID 37582470 DOI: 10.1016/j.jtct.2023.08.008 |
0.146 |
|
| 2021 |
Salas MQ, Atenafu EG, Law AD, Lam W, Pasic I, Chen C, Kim DDH, Michelis FV, Gerbitz A, Lipton JH, Mattsson J, Kumar R, Viswabandya A. Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia & Lymphoma. 1-11. PMID 34435547 DOI: 10.1080/10428194.2021.1966781 |
0.146 |
|
| 2021 |
Novitzky Basso I, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Kim DDH. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. European Journal of Haematology. PMID 33421199 DOI: 10.1111/ejh.13576 |
0.144 |
|
| 2022 |
Kimura M, Ferreira VH, Kothari S, Pasic I, Mattsson JI, Kulasingam V, Humar A, Mah A, Delisle JS, Ierullo M, Majchrzak-Kita B, Kumar D, Hosseini-Moghaddam SM. Safety and Immunogenicity after A Three-dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Transplantation and Cellular Therapy. PMID 35914727 DOI: 10.1016/j.jtct.2022.07.024 |
0.144 |
|
| 2024 |
Alfaro Moya T, Salas MQ, Santos Carreira A, Atenafu EG, Law AD, Lam W, Pasic I, Kim DDH, Michelis FV, Novitzky Basso I, Gerbitz A, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Bone Marrow Transplantation. PMID 38317015 DOI: 10.1038/s41409-024-02216-3 |
0.12 |
|
| 2020 |
Salas MQ, Ezzat S, Lam W, Law AD, Pasic I, Michelis FV, Kim DDH, Gerbitz A, Al-Shaibani Z, Viswabandya A, Kumar R, Mattsson J, Lipton JH. Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology. PMID 33047394 DOI: 10.1111/ejh.13531 |
0.081 |
|
| 2023 |
Grewal K, Herrity E, Pasic I. [Not Available]. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 195: E969-E970. PMID 37487612 DOI: 10.1503/cmaj.221433-f |
0.03 |
|
| 2023 |
Grewal K, Herrity E, Pasic I. Tumour lysis syndrome. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 195: E515. PMID 37040999 DOI: 10.1503/cmaj.221433 |
0.024 |
|
| Hide low-probability matches. |